<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Postgrad Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Postgrad Med</journal-id>
      <journal-id journal-id-type="publisher-id">JPGM</journal-id>
      <journal-title-group>
        <journal-title>Journal of Postgraduate Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-3859</issn>
      <issn pub-type="epub">0972-2823</issn>
      <publisher>
        <publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25766343</article-id>
      <article-id pub-id-type="pmc">4943425</article-id>
      <article-id pub-id-type="publisher-id">JPGM-61-109</article-id>
      <article-id pub-id-type="doi">10.4103/0022-3859.150451</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Adverse Drug Reaction Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A case of probable bemiparin-induced HIT type II managed with low-dose fondaparinux</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Koufakis</surname>
            <given-names>T</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsapakidis</surname>
            <given-names>K</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Margaritis</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gabranis</surname>
            <given-names>I</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
      </contrib-group>
      <aff id="aff1">Department of Internal Medicine, General Hospital of Larissa, Larissa, Greece</aff>
      <author-notes>
        <corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Theocharis Koufakis, E-mail: <email xlink:href="thkoyfak@hotmail.com">thkoyfak@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Apr-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>61</volume>
      <issue>2</issue>
      <fpage>109</fpage>
      <lpage>109</lpage>
      <permissions>
        <copyright-statement>Copyright: &#xA9; 2015 Journal of Postgraduate Medicine</copyright-statement>
        <copyright-year>2015</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>Heparin-induced thrombocytopenia (HIT) type II is an immune-mediated, acquired, prothrombotic disorder that follows heparin therapy. A significantly lower HIT frequency has been observed in patients who take low-molecular-weight heparin (LMWH) compared to those receiving unfractionated heparin (UFH).[<xref rid="ref1" ref-type="bibr">1</xref>] Bemiparin is a LMWH whose efficacy and safety in various clinical conditions has been established.[<xref rid="ref2" ref-type="bibr">2</xref>]</p>
    <p>We report the case of a 78-year-old woman, with a history of dementia, who presented to the Emergency Department of our hospital with complaints of abdominal pain. She had recently undergone a total hip arthroplasty, for which she had received bemiparin at a prophylactic dose (3500 IU, once a day). On Day 8 of bemiparin, her platelet count fell from 172.000/&#x3BC;L (pre bemiparin) to 45.000/&#x3BC;L and bemiparin was changed to fondaparinux (2.5 mg, once a day). She was subsequently discharged.</p>
    <p>The patient's main clinical and laboratory findings at the Emergency Department were as following: diffuse pain during the abdomen's deep palpation, sites of skin necrosis [<xref ref-type="fig" rid="F1">Figure 1</xref>], high serum LDH levels (1021 IU/L), thrombocytopenia (65.000/&#x3BC;L) and respiratory alkalosis from the arterial blood gas. A computed tomography (CT) angiography of chest and abdomen was performed which demonstrated a large pulmonary emboli at the right pulmonary artery, as well as thrombosis of the right common iliac and right common femoral veins. The patient's total 4T score for HIT was 8/8, while ELISA test and Serotonin Release Assay (SRA) for PF4-heparin antibodies proved to be strongly positive. The Naranjo algorithm, a method for estimating the probability of adverse drug reactions,[<xref rid="ref3" ref-type="bibr">3</xref>] produced a score equal to 7, suggesting a probable association between bemiparin and HIT development. She was maintained on fondaparinux at prophylactic and not therapeutic doses (2.5 mg, once a day), considering the patient's low body mass index (approximately 20 kg/m<sup>2</sup>) and the risk of bleeding complications. She was discharged 10 days later on fondaparinux and after a month, her platelet count was within the normal range. Fondaparinux was then replaced by acenocoumarol, with target INR of 2.5, for a time period of 3 months. In her follow-up visits she remained in good health and her blood tests were all within the normal range.</p>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Necrotic skin lesions at patient's arm</p>
      </caption>
      <graphic xlink:href="JPGM-61-109-g001"/>
    </fig>
    <p>In conclusion, we here report an uncommon case of bemiparin-associated severe HIT type II. LMWHs are widely used anticoagulants and physicians should be aware of this extremely rare but potentially lethal adverse effect. Moreover, as already demonstrated by other studies,[<xref rid="ref4" ref-type="bibr">4</xref>] fondaparinux can be an alternative, effective and safe agent for the treatment of HIT.</p>
  </body>
  <back>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>PS</given-names>
            </name>
          </person-group>
          <article-title>Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>2710</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">15985543</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ciccone</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Cortese</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Corbo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Corrales</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Al-Momen</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bemiparin an effective and safe low molecular weight heparin: A review</article-title>
          <source>Vascul Pharmacol</source>
          <year>2014</year>
          <fpage>32</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">24657810</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naranjo</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Busto</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Sandor</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ruiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A method for estimating the probability of adverse drug reactions</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>1981</year>
          <volume>30</volume>
          <fpage>239</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="pmid">7249508</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warkentin</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Pai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Schulman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Spyropoulos</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Eikelboom</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: A 30-month, 16-patient case series</article-title>
          <source>J Thromb Haemost</source>
          <year>2011</year>
          <volume>9</volume>
          <fpage>2389</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="pmid">21883878</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
